Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

Wangshu Liu, Tianli Xu, Mengjie Tang, Xueqin Wang, Jianbin Su, Feng Xu, Dongmei Zhang, Qing Zhu, Jie Cao, Hong WangResearch 2020 · DOI

Introduction

Cardiovascular disease (CAD) remains the leading cause of morbidity and mortality for individuals living with Type 2 Diabetes (T2D). While traditional lipid panels focusing on LDL and HDL cholesterol are standard clinical tools, researchers are increasingly turning to the Atherogenic Index of Plasma (AIP)—calculated as the log-transformed ratio of triglycerides to HDL-cholesterol—as a more sensitive predictor of arterial plaque buildup and cardiovascular risk.

In tandem with these lipid markers, Fibroblast Growth Factor 19 (FGF19) has emerged as a critical metabolic regulator. Produced in the gut, FGF19 plays a multifaceted role in bile acid synthesis, glucose metabolism, and lipid balance. While previous research suggested that FGF19 levels are lower in patients with established heart disease, its specific relationship with the AIP in diabetic populations has remained largely unexplored. This study sought to determine if serum FGF19 could serve as a reliable biomarker for cardiovascular risk in T2D patients.

Methods

The researchers conducted a cross-sectional study involving 200 T2D patients at the Affiliated Hospital 2 of Nantong University. The cohort included patients aged 20–75, excluding those with Type 1 diabetes, severe liver or kidney disease, or those currently taking statins that might alter lipid data.

  • Biochemical Analysis: Serum FGF19 levels were measured using a sandwich ELISA (Enzyme-Linked Immunosorbent Assay), and lipid profiles were determined via standard enzymatic analysis.
  • Calculations: The team calculated the AIP and the NAFLD (Non-Alcoholic Fatty Liver Disease) fibrosis score (NFS) to account for the interplay between liver health and metabolic hormones.
  • Statistical Modeling: Spearman’s correlation and multiple stepwise linear regression were employed to adjust for confounding variables, including age, sex, BMI, hypertension, and various antidiabetic treatments.

Key Results

The study identified a significant "sliding scale" effect: as a patient’s cardiovascular risk (AIP) increased, their levels of the potentially protective hormone FGF19 decreased. When patients were divided into tertiles based on their AIP scores, FGF19 concentrations showed a significant decreasing trend ($p < 0.05$).

The inverse relationship between serum FGF19 levels and the Atherogenic Index of Plasma (AIP) in T2D patients.

Spearman’s correlation analysis confirmed a significant negative relationship between the two markers ($r = -0.303, p < 0.01$). Furthermore, multiple linear regression demonstrated that AIP is an independent factor affecting serum FGF19 concentrations ($\\beta = -0.290, p < 0.01$), even after adjusting for a wide range of factors including BMI and NAFLD status.

The BMI Distinction

An interesting nuance emerged when the data was stratified by body mass. The negative correlation between FGF19 and AIP was particularly strong in normal-weight and overweight patients ($r = -0.330, p < 0.01$). However, this relationship was not statistically significant in obese T2D subjects. This suggests that in cases of severe obesity, other metabolic dysfunctions may suppress FGF19 levels to a baseline or otherwise obscure the relationship with lipid ratios.

Discussion and Conclusion

The findings suggest that serum FGF19 levels may act as a mirror for a patient's cardiovascular health. The authors propose that FGF19 might function as a protective factor; when its levels drop, the body's ability to maintain a healthy lipid balance is compromised, leading to a more atherogenic (plaque-forming) environment.

While this cross-sectional study cannot definitively prove that low FGF19 causes cardiovascular issues, the strong inverse association identifies it as a valuable potential biomarker for atherosclerosis in T2D patients, especially those who are not obese. Future longitudinal studies are needed to determine if therapies aimed at increasing FGF19 could effectively lower AIP and reduce the overall burden of heart disease in the diabetic population.

Summary updated

Abstract

Abstract Background We aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients. Methods Serum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated. Results T2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP ( p for trend &lt; 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level ( p &lt; 0.05 ). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant ( p &lt; 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) ( p &lt; 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p &lt; 0.01 ). Conclusions Serum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.
BibTeX
@inproceedings{liu2020inverse,
  author = {Wangshu Liu and Tianli Xu and Mengjie Tang and Xueqin Wang and Jianbin Su and Feng Xu and Dongmei Zhang and Qing Zhu and Jie Cao and Hong Wang},
  title = {{Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.2.24087/v1},
}
Figure